Overview
Location
United States, North Carolina, Durham
Employees
51-200
Founded date
1995
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 20, 2011 | Merck’s $430M bid for Inspire followed a 2009 offer | Inspire Pharmaceuticals (NASDAQ:ISPH) CEO Adrian Adams joined the North Carolina company in the winter of 2010 with goals of expanding its business beyond eye products and commercializing a breakthrough cystic fibrosis treatment. In January... |
| Apr 5, 2011 | Merck to buy Inspire Pharmaceuticals for $430M | Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| Mar 30, 2011 | Dry eye drug from Inspire gets patent extension in Japan | Diquafosol tetrasodium, marketed as Diquas, was launched in December by Japan-based drug partner Santen Pharmaceutical Co. Inspire and Santen entered into an agreement in 1998 that gave Santen an exclusive license to develop and market Diqu... |
| Mar 29, 2011 | North Carolina pharma R&D funding: A snapshot of 2010 | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Dry eye drug from Inspire gets patent extension in Japan | Two dry eye therapy patents owned by Inspire Pharmaceuticals (NASDAQ:ISPH) have received extensions in Japan, which gives the drug Diquas patent protection until February 2023. Raleigh, North Carolina-based Inspire disclosed in a securities... | |
| Merck’s $430M bid for Inspire followed a 2009 offer | Inspire Pharmaceuticals (NASDAQ:ISPH) CEO Adrian Adams joined the North Carolina company in the winter of 2010 with goals of expanding its business beyond eye products and commercializing a breakthrough cystic fibrosis treatment. In January... | |
| Merck to buy Inspire Pharmaceuticals for $430M | Merck (NYSE:MRK) is acquiring Raleigh, North Carolina-based Inspire Pharmaceuticals (NASDAQ:ISPH) for $430 million under a definitive agreement announced Tuesday. Under the agreement, a Merck subsidiary will commence a tender offer for all ... | |
| Inspire’s pink eye drug AzaSite draws generic challenge | Pink eye drug AzaSite, a major component of Inspire Pharmaceutical‘s (NASDAQ:ISPH) portfolio and one of the key products sought by Merck (NYSE:MRK) in its $430 million acquisition of the North Carolina company, could soon be facing generic ... | |
| North Carolina pharma R&D funding: A snapshot of 2010 | Research and development spending dollars reached a record $67.4 billion in 2010, a $1.5 billion increase compared with 2009. North Carolina’s life science companies are certainly part of that mix. A look at the annual reports from public c... |